Apimeds Pharmaceuticals US (APUS) Share-based Compensation (2025)

Apimeds Pharmaceuticals US (APUS) posted Share-based Compensation of $1.8 million for Q4 2025, up 4140.19% on a QoQ basis from $42674.0 in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Share-based Compensation (2025) Analysis & Trends

Apimeds Pharmaceuticals US's Share-based Compensation history runs 1 years deep, the most recent figure standing at $1.8 million for Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Share-based Compensation (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	43.00 Mn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	25.00 Mn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	125.69 Mn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	58.30 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	56.50 Mn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	55.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	21.00 Mn
10	Apimeds Pharmaceuticals US	8.17 Mn	8.17 Mn	-	1.81 Mn

Download Data